These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8241005)

  • 21. Hepatitis due to cyproterone acetate.
    Drakos PE; Gez E; Catane R
    Eur J Cancer; 1992; 28A(11):1931-2. PubMed ID: 1389539
    [No Abstract]   [Full Text] [Related]  

  • 22. Rhabdomyolysis in prostate cancer--caution in prescribing cyproterone acetate with statins.
    Ahamed E; Bissett D
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):528-9. PubMed ID: 15630845
    [No Abstract]   [Full Text] [Related]  

  • 23. Fatal fulminant hepatitis from cyproterone acetate.
    Hirsch D; Kovatz S; Bernheim J; Shenkman L
    Isr J Med Sci; 1994 Mar; 30(3):238-40. PubMed ID: 8181926
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis.
    Pu YS; Liu CM; Kao JH; Chen J; Lai MK
    Eur Urol; 1999 Oct; 36(4):293-7. PubMed ID: 10473987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatotoxicity induced by cyproteron acetate in the prostate carcinoma treatment - a case report].
    Vodička M; Sálek T; Röderová E; Cerný D
    Klin Onkol; 2013; 26(1):47-8. PubMed ID: 23528173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cyproterone acetate: cardiovascular tolerance].
    Hermabessière J
    Prog Urol; 1992 Apr; 2(2):226-33. PubMed ID: 1302058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma.
    Thorpe SC; Azmatullah S; Fellows GJ; Gingell JC; O'Boyle PJ
    Eur Urol; 1996; 29(1):47-54. PubMed ID: 8821690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
    Manso G; Thole Z; Salgueiro E; Revuelta P; Hidalgo A
    Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):253-9. PubMed ID: 16294367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.
    Macdonald AG; Bissett JD
    Clin Oncol (R Coll Radiol); 2001; 13(2):135-7. PubMed ID: 11373877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cirrhosis in a child with hypothalamic syndrome and central precocious puberty treated with cyproterone acetate.
    Garty BZ; Dinari G; Gellvan A; Kauli R
    Eur J Pediatr; 1999 May; 158(5):367-70. PubMed ID: 10333116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular damage by cyproterone acetate.
    Meijers WH; Willemse PH; Sleijfer DT; Mulder NH; Grond J
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1121-2. PubMed ID: 2946585
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of prostatic cancer with cyproterone acetate as monotherapy.
    Beurton D; Grall J; Davody P; Cukier J
    Prog Clin Biol Res; 1987; 243A():369-77. PubMed ID: 2958861
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.
    Holub G; Lunglmayr G; Spona J
    Urol Res; 1981; 9(5):245-7. PubMed ID: 6458145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fulminant hepatitis due to cyproterone acetate.
    Lévesque H; Trivalle C; Manchon ND; Vinel JP; Moore N; Hémet J; Courtois H; Bercoff E; Bourreille J
    Lancet; 1989 Jan; 1(8631):215-6. PubMed ID: 2563116
    [No Abstract]   [Full Text] [Related]  

  • 35. [Severe acute hepatitis due to cyproterone].
    Ruiz-Rebollo ML; Polo F; Palenzuela R; Moretó M
    Gastroenterol Hepatol; 1997; 20(7):385. PubMed ID: 9377242
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatocellular carcinoma during hormonotherapy for prostatic cancer.
    Kattan J; Spatz A; Culine S; Terrier-Lacombe MJ; Elias D; Droz JP
    Am J Clin Oncol; 1994 Oct; 17(5):390-2. PubMed ID: 8092108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyproterone acetate in the management of prostatic cancer.
    Tunn UW
    Prog Clin Biol Res; 1989; 303():105-10. PubMed ID: 2528734
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy of virginal prostatic cancer with cyproterone acetate].
    Maier U
    Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U
    Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.